Merrimack Consolidates MM-398 with $220M+ PharmaEngine Deal
By Tom Wall
Tuesday, May 10, 2011
Merrimack Pharmaceuticals Inc. consolidated its development and commercialization program for MM-398/PEP02 by acquiring rights for Europe and Asia from PharmaEngine Inc., of Taipei, Taiwan, for $10 million up front, a potential $210 million in milestones, and tiered royalties on sales.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.